uPRAX acquires funding from MIT 2018 for feasibility study

uPRAX have acquired a grant of 25.000 euro from the Province of South Holland (Provincie Zuid Holland) for part of a feasibility study into the necessary universality of microneedle applicators. This funding will help uPRAX in the development from the Adjustable Precision Applicator (APA) to a consumer-centric version of the device, by enabling research into which insertion parameters can best be varied in applicators in order to provide a complete product portfolio that will provide solutions for all different microneedle technologies.


MICRONEEDLES 2018 Conference in Vancouver

From the 29th of May till the 1st of June the uPRAX founders attended the 5th International Microneedle Conference at the University of British Columbia in Vancouver, Canada. The Conference provided a unique international forum for academics and industry involved in the design, development, application and clinical translation of microneedle technology. At the conference uPRAX held a poster presentation highlighting the upcoming publication that demonstrates the  variance in penetration efficiency and percentage of delivered antigen is related to the amount of velocity or pressing force. Therefor this was a perfect opportunity to demonstrate to all attendants the importance of consistent microneedle insertion and the importance of application technology.

Opening ceremony in National Historic Museum